Dear Label_Name,

Greetings! I hope you are well.

I am writing on behalf of an international publishing house, Science and Education Publishing, USA (http://www.sciepub.com).

Science and Education Publishing (SciEP) is a multidisciplinary open access publisher of Journals covering the fields of Science, Technology and Medicine. All SciEP publications are subject to high-quality peer review, editorial and production processes and are freely available online.

Welcome to the April, 2013 edition of SciEP newsletter, providing monthly summaries of articles on science & education related topics of interest to scientist and professionals. The mission of our journals is to provide an open access forum for publishing new findings on issues pertinent to scientific and academic field. We also invite you to submit original research papers, review articles, short reports, or case studies are considered for publication in our Multidisciplinary Journals.

American Journal of Public Health Research
DOI: 10.12691/ajphr-1-1-3

The Implementation of a Tele-Homecare System with Service Oriented Architecture and HL7 Message Transmission Standard
Ching-Sung Wang

American Journal of Medical and Biological Research
DOI: 10.12691/ajmbr-1-1-2

The Influence of Ethanol on Pyruvate Kinases Activity in Vivo, in Vitro, in Silico
Lelevich Sergey Vladimirovich, Khrustalev Vladislav Victorovich, Barkovsky Eugene Victorovich, Shedogubova Tatyana Aleksandrovna

American Journal of Medical Sciences and Medicine
DOI: 10.12691/ajmsm-1-1-1

Clinical and Histological Features in Wegener Granulomatosis
Li Cavoli Gioacchino, Passantino Rita, Bono Luisa, Tortorici Calogera, Ferrantelli Angelo, Giammarresi Carlo, Rotolo Ugo

American Journal of Infectious Diseases and Microbiology
DOI: 10.12691/ajidm-1-1-2

The Curse of Lymphatic Filariasis: Would the Continual Use of Diethylcarbamazine Eliminate this Scourge in Papua New Guinea?
Anne Lanham, Lillian Mwanri

We have released issues of some journals on February 2013.
American Journal of Public Health Research
American Journal of Medical Sciences and Medicine
American Journal of Medical and Biological Research
American Journal of Pharmacological Sciences
American Journal of Clinical Medicine Research
American Journal of Nursing Research
American Journal of Cancer Prevention
American Journal of Medicine Studies
American Journal of Infectious Diseases and Microbiology
American Journal of Cardiovascular Disease Research
American Journal of Biomedical Research
American Journal of Mechanical Engineering
American Journal of Microbiological Research
Journal of Preventive Medicine
American Journal of Food and Nutrition
American Journal of Hypertension Research
American Journal of Sports Science and Medicine
Journal of Cancer Research and Treatment
American Journal of Zoological Research
Journal of Biomedical Engineering and Technology
American Journal of Microbiological Research
Biomedical Science and Engineering

We are pleased to announce that submissions are now being accepted for peer review for all the journals across all our subject areas in SciEP.

Please submit your manuscript via our online submission system:
http://www.sciepub.com/author/signin

To unsubscribe from our mailing list, please click on the following link: unsubscribe

I am looking forward to hearing from you.

Kind regards,

David Rain
Email:join@sciepub.com
Science and Education Publishing (http://www.sciepub.com)

Inpatient Hospital Costs for Celiac Disease in the United States in 2014

Eric P. Borrelli

University of Rhode Island, College of Pharmacy, Kingston, Rhode Island, United States

Abstract: Celiac disease (CD) is a rare autoimmune disease that affects approximately 0.5 to1% of the United States (U.S.) population. Patients with CD have gastrointestinal disturbances resulting from eating gluten. The only treatment therapy available is maintaining a strict gluten free diet. Currently, there is not much published data detailing the direct cost of CD in the U.S. This study analyzed direct inpatient hospitalization costs of CD in the U.S. The Healthcare Cost and Utilization Project net (HCUPnet) was analyzed to determine the number of discharges, mean length of stay, mean cost per hospitalization, and total expenditures of several patient demographics in the U.S. for the year 2014. There were 805 discharges in 2014 in the U.S. The mean cost per hospitalization was $9,247 (SD $17,732) and the mean length of stay was 4.9 days. The aggregate cost of celiac in the in 2014 was $7,413,355 (SD $23,320,823). Different patient demographics resulted in variable costs and length of stay for patients. The mean cost of hospitalization for CD was lower than that of the general population in the across all disease states. With no approved cures or treatment, CD will contribute to health expenditures in the U.S. for the foreseeable future.

Keywords: celiac disease, cost, health economics, epidemiology

Citation: Eric P. Borrelli, Inpatient Hospital Costs for Celiac Disease in the United States in 2014. International Journal of Celiac Disease, 5 (3). 111-114. January 2017. doi:10.12691/ijcd-5-3-2

1. Introduction

Celiac disease (CD) is an autoimmune disease that affects approximately 0.5 to 1% of the population in the United States (U.S.) [1,2,3]. CD causes gastrointestinal disturbances such as mucosal inflammation of the small intestine and architectural changes to the gastrointestinal tract to patients who ingest gluten [4,5]. Architectural changes include several different types of lesions to the small intestine including hyperplastic lesions, destructive lesions, and hypoplastic lesions as well as villous atrophy [4,5,6,7,8]. General symptoms that are observed include diarrhea, dyspepsia, abdominal pain, steatorrhea, weight loss, and malabsorption [4]. Patients can also present asymptomatically or with non-intestinal symptoms such as osteoporosis, anemia, and dental issues [9]. There is evidence that shows strong correlation of family history of CD in patients [10,11]. Evidences also show that both adult and pediatric patients with CD tend to be shorter in height compared to the general population [12,13]. There is a higher prevalence of females with CD compared to males [14,15,16]. Currently there is no cure nor a U.S. Food and Drug Administration (FDA) approved drug for the treatment of CD. The main treatment therapy for patients with CD is a strict gluten free diet [17]. One hundred percent compliance with a strict gluten free diet may be difficult. Patients who unknowingly eat food contaminated with gluten, even with cross contamination, may suffer adverse effects which require medical treatment. In the United Kingdom, a sample of 3,646 patients saw their average annual health expenditure increase by an average of £310 [18]. A study performed in the U.S. found that patients with CD had on average $3,964 more in medical expenses over a 4-year period compared to patients without CD [19]. Currently, there is not much published data regarding the direct cost of CD in the U.S.. This study tried to describe the direct cost of inpatient hospitalization for CD in the U.S. for the year 2014.

2. Material and Methods

An analysis was performed of the U.S. National Inpatient Sample (NIS) of the Healthcare Cost and Utilization Project Net (HCUPnet) for the year 2014 using the primary International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis code: 579.0 celiac disease [20]. The Nationwide Emergency Department Sample (NEDS) of HCUPnet was also utilized to look at emergency room discharges in the U.S. for CD [20]. HCUPnet is the largest publicly available online query system of all-payer healthcare databases. HCUPnet is part of HCUP of the Agency for Healthcare Research and Quality (AHRQ). The patient demographics of sex, age, and geographic region were analyzed. Sex was categorized as either male or female. Age was organized into different groups such as 1 to 44 years, 45 to 64 years, and 65 to 84 years old. There was not enough data available to accurately describe the hospitalizations for patients 85 years and older. Geographic region was divided into Northeast, South, Midwest, and West as defined by the U.S. Census Bureau [21]. The outcomes that were measured were number of discharges, length of stay (LOS) in days, mean cost per hospitalization in 2014 U.S. dollars, and total expenditure in 2014 U.S. dollars.

3. Results

3.1. Discharges

The HCUPnet analysis indicated that there were 805 inpatient hospital discharges in 2014 in the U.S. with the primary diagnosis of CD (Table 1). There were also an additional 752 emergency room visits with the primary diagnosis of CD in 2014 in the U.S. There were 510 females discharged from the hospital for CD compared to 295 males. There were 125 patients discharged aged 1 to 17 years old, 230 patients discharged aged 18 to 44, 170 patients discharged aged 45 to 64, and 245 patients discharged aged 65 to 84 years old. The number of discharges for each geographic region were as follows: 190 in the Northeast, 290 in the South, 175 in the Midwest, and 150 in the West.

Table 1. The number of discharges, length of stay (in days), mean cost per hospitalization (in $), and total expenditure (in $) for each patient demographic analyzed

3.2. Length of Stay

The mean LOS per hospitalization for patients with CD in 2014 in the U.S. was 4.9 days. The mean LOS ranged from 4.5 days to 5.2 days for all patient demographics except patients aged 18 to 44 years old who had a mean LOS of 3.7 days and patients aged 65 to 84 years old who had a mean LOS of 6.3 days.

3.3. Mean Cost

The mean cost per hospitalization for patients with CD was $9,247 (Standard Deviation {SD} $17,732) (Chart 1). This is lower than the mean cost of hospitalization for the general population in the U.S. across all disease states ($10,885). The mean cost per hospitalization varied slightly by gender with males having a mean cost of $10,699 (SD $22,963) compared to females with a mean cost of $8,403 (SD $12,692). Patients aged 65 to 84 years old had the highest mean cost compared to all other age groups with a cost of $10,830 (SD $19,879). The next age group with the highest mean cost was patients aged 1 to 17 years old with a mean cost of $10,612 (SD $19,789), followed by patients aged 45 to 64 years old costing $8,764 (SD $18,423) per hospitalization, and lastly patients aged 18 to 44 years old having a mean cost of $7,174 (SD $9,600). The geographic region with the highest mean cost per hospitalization was the West at $12,937 (SD $18,224). The Northeast was second with a mean cost of hospitalization of $10,072 (SD $24,081). The South had the third highest mean cost per hospitalization of $8,055 (SD $12,091) and lastly the Midwest had a mean cost of $7,315 (SD $7,461). The aggregate cost of CD in the U.S. in 2014 was $7,413,355 (SD $23,320,823).

Chart 1. The mean cost of hospitalization for Celiac Disease in the United States in 2014 broken down into specific patient demographics. Costs are in U.S. dollars

4. Discussion

The cost of hospitalization for CD in 2014 was lower than the cost of hospitalization in the general population across all disease states. CD is estimated to be underdiagnosed and patients may have CD without even knowing it [22,23,24]. They may present to the hospital with an episode of general symptoms such as dyspepsia or malabsorption not knowing that it is secondary to CD. The cost of hospitalization for dyspepsia and malabsorption were very similar with dyspepsia costing $9,154 per hospitalization in 2014 and intestinal malabsorption costing $9,029 per hospitalization [20]. These are both very close to the mean cost of hospitalization for CD of $9,247. In 2014 there were more hospitalizations for CD in females compared to males, which is consistent with previous evidence that CD is more common in women [14,15,16]. In this study, males had a higher cost per hospitalization compared to females ($10,699 vs $8,403) as well as a longer mean length of stay (5.2 days vs 4.7 days). A previous study found that males with CD had medical expenses on average more than $10,000 more than males without CD [19]. There is some evidence that CD is more severe in males which might explain the higher mean cost and longer mean LOS in males for 2014 [25,26]. In 2014, the South had the highest number of hospital discharges with CD per geographic region with the Northeast having the second highest. This is the not consistent with a recent study that showed that the risk of CD in the Northeast was more than twice that of the South [27]. One reason that may explain the differing results is that this study only looked at hospitalizations whereas Unalp-Arida A, et al. looked at incidence of CD in the U.S.. There may be an unknown reason that caused more patients in the South to be hospitalized due to complications with their CD compared to the Northeast, despite the higher prevalence of CD patients in the Northeast. Depending on the geographic region of a patient with CD, the cost of hospitalization may vary. The West had the highest cost of hospitalization for CD followed by the Northeast, which is consistent with the highest cost of hospitalization in the general population of all disease states in the U.S. in 2012 [28].

Further research is needed to find explanations as to why certain patient demographics and characteristics for CD result in different LOS and cost per hospitalization. Additional research is needed to analyze to cost of CD in the U.S. in the inpatient and outpatient settings.

5. Conclusion

The mean cost of hospitalization for CD in the U.S. was lower than that of the general population in the U.S. across all disease states. Different patient demographics and characteristics resulted in variable length of stays and costs per hospitalization.

References

[1]   | Rubio-Tapia A, Ludvigsson JF, Brantner TL, Murray JA, Everhart JE. The prevalence of celiac disease in the . Am J Gastroenterol. 2012 Oct; 107(10): 1538-44

[2]  
Fasano A, Berti I, Gerarduzzi T, Not T, Colletti RB, Drago S, Elitsur Y, Green PH, Guandalini S, Hill ID, Pietzak M, Ventura A, Thorpe M, Kryszak D, Fornaroli F, Wasserman SS, Murray JA, Horvath K. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med. 2003 Feb 10; 163(3): 286-92.

[3]  
Dubé C, Rostom A, Sy R, Cranney A, Saloojee N, Garritty C, Sampson M, Zhang L, Yazdi F, Mamaladze V, Pan I, Macneil J, Mack D, Patel D, Moher D. The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review. Gastroenterology. 2005 Apr; 128(4 Suppl 1): S57-67.

[4]   | Gujral N, Freeman HJ, Thomson AB. Celiac disease: Prevalence, diagnosis, pathogenesis and treatment. World Journal of Gastroenterology: WJG. 2012; 18(42): 6036-6059.
[5]   | Perera DR, Weinstein WM, Rubin CE. Symposium on pathology of the gastrointestinal tract-Part II. Small intestinal biopsy. Hum Pathol. 1975 Mar; 6(2):157-217.
[6]   | Marsh MN. Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity (‘celiac sprue’) Gastroenterology. 1992; 102: 330-354.
[7]   | Oberhuber G, Granditsch G, Vogelsang H. The histopathology of coeliac disease: time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol. 1999; 11: 1185-1194.

[8]  
Rostami K, Mulder CJ, Werre JM, van Beukelen FR, Kerchhaert J, Crusius JB, Peña AS, Willekens FL, Meijer JW. High prevalence of celiac disease in apparently healthy blood donors suggests a high prevalence of undiagnosed celiac disease in the Dutch population. Scand J Gastroenterol. 1999; 34: 276-279.

[9]   | Rampertab SD, Pooran N, Brar P, Singh P, Green PH. Trends in the presentation of celiac disease. Am J Med. 2006; 119: 355. e9-355.14.
[10]   | Rubio-Tapia A, Van Dyke CT, Lahr BD, Zinsmeister AR, El-Youssef M, Moore SB, Bowman M, Burgart LJ, Melton LJ, 3rd, Murray JA. Predictors of family risk for celiac disease: a population-based study. Clin Gastroenterol Hepatol. 2008; 6: 983-7.
[11]   | Book L, Zone JJ, Neuhausen SL. Prevalence of celiac disease among relatives of sib pairs with celiac disease in U.S. families. Am J Gastroenterol. 2003 Feb; 98(2): 377-81.
[12]   | Esmaeilzadeh A, Ganji A, Goshayeshi L, Ghafarzadegan K, Afzal Aghayee M, Mosanen Mozafari H, Saadatniya H, Hayatbakhs A, Ghavami Ghanbarabadi V. Adult Celiac Disease: Patients Are Shorter Compared with Their Peers in the General Population. Middle East J Dig Dis. 2016 Oct; 8(4): 303-309.
[13]   | Cosnes J, Cosnes C, Cosnes A, Contou JF, Reijasse D, Carbonnel F, Beaugerie L, Gendre JP. [Undiagnosed celiac disease in childhood]. Gastroenterol Clin Biol. 2002 Jun-Jul; 26(6-7): 616-23.
[14]   | Shah S, Leffler D. Celiac disease: an underappreciated issue in women’s health. Womens Health (Lond). 2010 Sep; 6(5): 753-66.
[15]   | Megiorni F, Mora B, Bonamico M, Barbato M, Montuori M, Viola F, Trabace S, Mazzilli MC. HLA-DQ and susceptibility to celiac disease: evidence for gender differences and parent-of-origin effects. Am J Gastroenterol. 2008 Apr; 103(4): 997-1003.
[16]   | Green PHR, Stavropoulos SN, Panagi SG, Goldstein SL, Mcmahon DJ, Absan H, Neugut AI. Characteristics of adult celiac disease in the USA: results of a national survey. Am J Gastroenterol. 2001 Jan; 96(1): 126-31.
[17]   | Chou R, Bougatsos C, Blazina I, Mackey K, Grusing S, Selph S. Screening for Celiac Disease: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2017 Mar 28; 317(12): 1258-1268.
[18]   | Violato M, Gray A, Papanicolas I, Ouellet M. Resource Use and Costs Associated with Coeliac Disease before and after Diagnosis in 3,646 Cases: Results of a UK Primary Care Database Analysis. Singh SR, ed. PLoS ONE. 2012; 7(7): e41308.
[19]   | Long KH, RubioO-Tapia A, Wagie AE, et al. The economics of celiac disease: a population-based study. Alimentary pharmacology & therapeutics. 2010; 32(2): 261-269.
[20]   | HCUPnet. Healthcare Cost and Utilization Project (HCUP). 2014. Agency for Healthcare Research and Quality, Rockville, MD. http://hcupnet.ahrq.gov/ Accessed May 5, 2017.
[21]   | US Census Bureau. Population and housing unit estimates: Guidance for geographies users. https://www.census.gov/programs-surveys/popest/guidance-geographies/terms-and-definitions.html Accessed May 5, 2017.
[22]   | Fasano A, Catassi C. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Gastroenterology. 2001; 120(3): 636–51.
[23]   | Mohammadibakhsh R, Sohrabi R, Salemi M, Mirghaed MT, Behzadifar M. Celiac disease in Iran: a systematic review and meta-analysis. Electronic Physician. 2017; 9(3): 3883-3895.
[24]   | Kolimarala V, Vasita E, Banoub H, Chong SKF. Seronegative Coeliac Disease in Children: A Case Report and Review of the Literature. Case Reports in Pediatrics. 2017; 2017: 1652052.
[25]   | Bai D, Brar P, Holleran S, Ramakrishnan R, Green PH. Effect of gender on the manifestations of celiac disease: evidence for greater malabsorption in men. Scand J Gastroenterol. 2005; 40: 183-7.
[26]   | Bardella MT, Fredella C, Saladino V, Trovato C, Cesana BM, Quatrini M, Prampolini L. Gluten intolerance: gender- and age-related differences in symptoms. Scand J Gastroenterol. 2005; 40: 15-9.
[27]   | Unalp-Arida A, Ruhl CE, Choung RS, Brantner TL, Murray JA. Lower Prevalence of Celiac Disease and Gluten-Related Disorders in Persons Living in Southern vs Northern Latitudes of the United States. Gastroenterology. 2017 Feb 24. pii: S0016-5085(17)30176-2.

[28]  
Weiss AJ, Elixhauser A. Overview of Hospital Stays in the United States, 2012: Statistical Brief #180. 2014 Oct. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006 Feb-. Available from http://www.ncbi.nlm.nih.gov/books/NBK259100/.